Talk:Dopamine receptor

From Wikipedia, the free encyclopedia

	MCB Portal This article is within the scope of the Molecular and Cellular Biology WikiProject. To participate, visit the WikiProject for more information. The WikiProject's current monthly collaboration is focused on improving Restriction enzyme.
B	This article has been rated as B-Class on the assessment scale.
Top	This article is on a subject of Top-importance within molecular and cellular biology.
Article Grading: The article has been rated for quality and/or importance but has no comments yet. If appropriate, please review the article and then leave comments here to identify the strengths and weaknesses of the article and what work it will need.

This page has been a stub for a very long time.--Kintaro 06:47, 30 Apr 2005 (UTC)

maybe we ought to take out the headings of each type of receptor for now, since they all say the same thing, and just have a sentence about the types. Then we can put them back in when we have more to add. It looks kinda weird now. What do you think?--Delldot 05:52, 8 October 2005 (UTC)

Personally I find the current layout to be ideal. Leaving it room to grow doesn't mishape it to much and welcomes in additions. Imo it should stay as is.Foolishben 08:16, 9 August 2007 (UTC)

[edit] merge subtypes

I think the separate articles on the D1 to D5 receptors are too small to merit their own page. It is probably better to merge all these pages into one article. When the information on a particular receptors grows sufficiently large, it can then be specified as a main article Kpmiyapuram (talk) 16:30, 2 April 2008 (UTC)

You know...it's been on my "to do" list for a while to expand each of these. Hopefully I can muster the spare time & energy to finally get crackin' on that... — Scientizzle 16:44, 2 April 2008 (UTC)

There is already sufficient information in the literature, especially related to pharmacology of dopamine receptor subtypes to justify a separate article on each. In fact some of this information has recently been added (e.g., subtype selective ligands). These receptors are of high interest as therapeutic targets to the pharmaceutical industry and the development of subtype selective ligands is a very promising way of dissociating desirable therapeutic from undesirable side effects, so the amount of information will only grow over time. Therefore I strongly oppose merging these articles. Cheers. Boghog2 (talk) 18:20, 2 April 2008 (UTC)